|
1. |
Clinical Pharmacokinetics 1990 |
|
Clinical Pharmacokinetics,
Volume 18,
Issue 1,
1990,
Page 1-19
Gary R. Matzke,
Wendy L. St Peter,
Preview
|
PDF (8626KB)
|
|
ISSN:0312-5963
出版商:ADIS
年代:1990
数据来源: ADIS
|
2. |
Plasma Protein Binding of Drugs in Pregnancy and in Neonates |
|
Clinical Pharmacokinetics,
Volume 18,
Issue 1,
1990,
Page 20-36
Lidia J. Notarianni,
Preview
|
PDF (7620KB)
|
|
摘要:
Plasma protein binding of drugs has important implications for drug disposition and action since it is the first, and controlling, step in drug distribution. Physiological changes in pregnancy include significant changes in plasma composition which affect drug binding and subsequent drug response; the extent of these changes depends on the stage of gestation. Both albumin and &agr;1-acid glycoprotein fractions are reduced, and consequently the binding of both acidic and basic drugs may be affected. This may lead to difficulties in maintaining adequate plasma concentrations of highly protein-bound drugs, since the measurement of total drug concentration in plasma may no longer be a valid indicator for dose adjustment.The newborn infant displays a continually changing plasma profile. The presence of fetal proteins and endogenous substrates known to interfere with drug binding can lead to unexpected complications due to a higher than expected ‘free’ drug fraction. Furthermore, a decrease in the affinity of albumin for bilirubin during this period may lead to bilirubin displacement by drugs such as diazepam, sulphonamides and salicylate, resulting in clinical jaundice which would not occur beyond the neonatal period. Plasma composition and its effect on drug binding should be taken into account when prescribing highly protein bound drugs with narrow therapeutic: toxic ratios.
ISSN:0312-5963
出版商:ADIS
年代:1990
数据来源: ADIS
|
3. |
Pharmacokinetic Drug Interactions with Phenytoin (Part I)1 |
|
Clinical Pharmacokinetics,
Volume 18,
Issue 1,
1990,
Page 37-60
Roger L. Nation,
Allan M. Evans,
Robert W. Milne,
Preview
|
PDF (11036KB)
|
|
摘要:
Phenytoin, which is used primarily as an anticonvulsant agent, has a relatively low therapeutic index, and monitoring of plasma phenytoin concentration is often used to help guide therapy. It has properties which predispose it to an involvement in pharmacokinetic interactions, a large number of which have been reported. These properties include: low aqueous solubility and slow rate of gastrointestinal absorption; a relatively high degree of plasma protein binding; a clearance that is non-linear due to saturable oxidative biotransformation; and the ability to induce hepatic microsomal enzymes.Because of its narrow therapeutic range, drug interactions leading to alterations in plasma phenytoin concentration may be clinically important. Such interactions have often been reported initially as either cases of phenytoin intoxication or of decreased effectiveness. Drugs may modify the pharmacokinetics of phenytoin by altering its absorption, plasma protein binding, or hepatic biotransformation; alterations in the absorption and/or biotransformation may lead to changes in both the unbound plasma phenytoin concentration and, as a result, the clinical effect. Preparations which may decrease the gastrointestinal absorption of phenytoin include nutritional formulae and charcoal. There are many reports of drugs which may increase (e.g. folic acid, dexamethasone and rifampicin) or decrease (e.g. valproic acid, sulthiame, isoniazid, cimetidine, phenylbutazone, chloramphenicol and some sulphonamides) the metabolism of phenytoin. It is important to bear in mind that, as a result of its non-linear clearance, changes in phenytoin absorption and/or biotransformation will lead to more than proportionate changes in plasma drug concentration. Drugs which may displace phenytoin from plasma albumin include valproic acid, salicylic acid, phenylbutazone and some sulphonamides. Although an alteration in the unbound fraction of phenytoin in plasma would not, in itself, be expected to alter the unbound plasma phenytoin concentration, the interpretation of total plasma concentrations for therapeutic drug monitoring may be confounded. Some drugs appear to alter phenytoin pharmacokinetics via dual mechanisms (e.g. valproic acid and phenylbutazone), while for other compounds the mechanism of interaction has not been fully elucidated.Phenytoin has been reported to alter the pharmacokinetics of a large number of drugs. The majority of these interactions arise because phenytoin is a potent inducer of cytochrome P450 microsomal enzymes, and therefore may increase the clearance of drugs which are extensively metabolised; drugs affected include carbamazepine, theophylline, methadone, prednisolone, dexamethasone, metyrapone and several cardiac antiarrhythmic agents. With all of these, the resultant decrease in plasma concentrations may be clinically important. Current evidence suggests that the various cytochrome P450 isozymes may be affected differentially and, therefore, that the metabolic clearance of some drugs may be more sensitive to the enzyme-inducing effects of phenytoin. In addition, phenytoin also appears to increase the clearance of some drugs which are eliminated predominantly by conjugation reactions [e.g. paracetamol (acetaminophen) and oxazepam]. Interestingly, phenytoin has been reported to decrease the metabolic clearance of a commonly coadministered anticonvulsant, phenobarbital. For a few compounds only [e.g. furosemide (frusemide) and thyroxine], it has been suggested that phenytoin decreases gastrointestinal absorption. Although the binding of drugs to plasma albumin is largely unaffected by this agent, plasma levels of &agr;1-acid glycoprotein and sex hormone binding globulin may increase during phenytoin treatment, thereby altering the binding of some compounds.
ISSN:0312-5963
出版商:ADIS
年代:1990
数据来源: ADIS
|
4. |
Clinical Significance of Pharmacokinetic Models of Hepatic Elimination |
|
Clinical Pharmacokinetics,
Volume 18,
Issue 1,
1990,
Page 61-76
Denis J. Morgan,
Richard A. Smallwood,
Preview
|
PDF (7400KB)
|
|
摘要:
Various pharmacokinetic models, both simple and complex, have been developed to describe the way in which the rate of hepatic elimination of drugs depends on hepatic blood flow, hepatic intrinsic clearance and unbound fraction of drug in blood. A model is necessary because it is not possible to measure the average blood concentration of drug within the liver, i.e. the concentration at the site of drug elimination. However, the predictions of these models can differ markedly for drugs of high hepatic clearance, especially with the oral route of administration. Investigations of the models have mostly involved studies within vitroexperimental preparations, such as isolated perfused livers. While such studies have advanced our understanding of the mechanism of hepatic uptake and elimination processes, the implications for clinical drug usage have been somewhat neglected.Use of one of the available models is necessary for the assessment of the capacity ofin vivohepatic drug metabolism processes (i.e. hepatic intrinsic clearance) and for predicting the effect of increasing dose on blood concentrations of high clearance drugs exhibiting Michaelis-Menten elimination kinetics, especially those that undergo a nonlinear hepatic first-pass effect. Clinically significant differences between the models can occur under these circumstances. A model is also required for quantitative prediction of the effect on blood drug concentrations of changes in hepatic blood flow, hepatic intrinsic clearance or drug-protein binding in blood. It is in predicting these changes that differences of major clinical significance can occur between the models. The greatest differences are seen in predicting the effect for orally administered drugs of changes of hepatic blood flow on blood concentrations, and changes of protein binding on unbound blood concentrations of drug. These changes can result from disease processes, altered physiology (old age or pregnancy), food intake or concomitant administration of other drugs. A model is also required for determining the mechanism by which such clinical changes occur.When considering these effects on hepatic elimination, it is essential to appreciate that the conclusions may depend markedly on the particular model chosen. Until more data on the applicability of the models are obtained in humans, the undistributed sinusoidal and venous equilibrium models, which represent the opposite extremes of behaviour among the available models, should both be used in assessing hepatic drug elimination.
ISSN:0312-5963
出版商:ADIS
年代:1990
数据来源: ADIS
|
5. |
FamotidinePharmacokinetic Properties and Suppression of Acid Secretion in Paediatric Patients Following Cardiac Surgery |
|
Clinical Pharmacokinetics,
Volume 18,
Issue 1,
1990,
Page 77-81
G. Kraus,
D.R. Krishna,
D. Chmelarsch,
M. Schmid,
U. Klotz,
Preview
|
PDF (2019KB)
|
|
摘要:
The pharmacokinetic and pharmacodynamic properties of the H2-receptor antagonist famotidine have been well described in adult subjects. However, similar data for children are not available. Therefore, this study looked at the disposition of the drug (given to prevent aspiration following cardiac surgery) in 10 paediatric patients with normal kidney function (age range 2 to 7 years, bodyweight 14 to 25kg) after a single intravenous dose of famotidine 0.3 mg/kg. Plasma concentrations of the drug and gastric pH values were both monitored for 20 hours by high performance liquid chromatography and aspiration of gastric juice, respectively. Plasma famotidine concentrations declined with an elimination half-life of 3.3 ± 1.8h (mean ± SD) and the drug was effective in elevating the gastric pH above 3.5 for about 9 hours in 6 patients. The variable volume of distribution and total plasma clearance of famotidine averaged 1.4 ± 1.0 L/kg and 0.3 ± 0.17 L/h/kg, respectively. In 4 patients unchanged famotidine could also be measured in a 12-hour urine fraction. The amount excreted (21 to 79%) correlated with clearance (r = 0.97). All these data are comparable to those obtained in healthy adults, indicating that paediatric patients receiving intensive medical treatment after cardiac surgery can handle famotidine in a way very similar to healthy adult subjects. A dosage of 0.3 mg/kg every 8 hours appears to be advisable.
ISSN:0312-5963
出版商:ADIS
年代:1990
数据来源: ADIS
|
6. |
Scintigraphic Study of Radiolabelled Interferon-&agr; in Osteosarcoma Patients |
|
Clinical Pharmacokinetics,
Volume 18,
Issue 1,
1990,
Page 82-89
R.A. Diez,
B. Perdereau,
M. Peter,
T. Dorval,
R. Gongora,
E.T. Falcoff,
Preview
|
PDF (3255KB)
|
|
摘要:
Interferon-&agr; is currently under evaluation as an antineoplastic agent in several types of tumour. Despite its clearin vitroeffects, the effectiveness of interferonin vivois limited. To assess whether this discrepancy reflects pharmacokinetic limitations, the authors analysed interferon distribution in 2 osteosarcoma patients by scintigraphy using123I-interferon-&agr;-2a. Numerical analysis of the scintigraphic records demonstrated that the main organs of elimination were the kidneys, when the calculation was made on the basis of surface area. On the other hand, the apparent total uptake by liver (whose projection surface - i.e the area exposed to the lens - is greater) was higher, reaching about 25 to 30% of the injected dose. The projection surface of the tumour was able to take up radiolabelled interferon in both cases, resulting in a 4-fold increase in the external radiation count compared with the equivalent region of the contralateral limb (although it is not possible to determine whether the label is present on the tumour itself or on the surrounding inflammatory cells). Thus, interferon-&agr; seems able to reach at least the immediate neighbourhood of osteosarcoma mass.
ISSN:0312-5963
出版商:ADIS
年代:1990
数据来源: ADIS
|
|